

**FNIP2 Antibody**  
**Catalog # ASC10858****Specification****FNIP2 Antibody - Product Information**

Application	WB, E
Primary Accession	<a href="#">Q9P278</a>
Other Accession	<a href="#">NP_065891</a> , <a href="#">154689769</a>
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application Notes	FNIP2 antibody can be used for detection of FNIP2 by Western blot at 1 - 2 µg/mL.

**FNIP2 Antibody - Additional Information**Gene ID **57600****Target/Specificity**

FNIP2; Multiple isoforms of FNIP2 are known to exist. This antibody is predicted to not cross-react with FNIP1.

**Reconstitution & Storage**

FNIP2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

**Precautions**

FNIP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**FNIP2 Antibody - Protein Information**

**Name** FNIP2 {ECO:0000303|PubMed:18663353, ECO:0000312|HGNC:HGNC:29280}

**Function**

Binding partner of the GTPase-activating protein FLCN: involved in the cellular response to amino acid availability by regulating the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:<a href="http://www.uniprot.org/citations/18663353" target="\_blank">18663353</a>, PubMed:<a href="http://www.uniprot.org/citations/31672913" target="\_blank">31672913</a>, PubMed:<a href="http://www.uniprot.org/citations/36103527" target="\_blank">36103527</a>). Required to promote FLCN recruitment to lysosomes and interaction with Rag GTPases, leading to activation of the non- canonical mTORC1 signaling (By similarity). In low-amino acid conditions, component of the lysosomal folliculin complex (LFC) on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, thereby inactivating mTORC1 and promoting nuclear translocation of TFEB and TFE3 (PubMed:<a href="http://www.uniprot.org/citations/31672913" target="\_blank">31672913</a>, PubMed:<a href="http://www.uniprot.org/citations/36103527" target="\_blank">36103527</a>). Upon amino acid restimulation, disassembly of the LFC complex liberates the GTPase- activating activity of

FLCN, leading to activation of mTORC1 and subsequent inactivation of TFEB and TFE3 (PubMed:<a href="http://www.uniprot.org/citations/31672913" target="\_blank">31672913</a>). Together with FLCN, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:<a href="http://www.uniprot.org/citations/25126726" target="\_blank">25126726</a>). In addition to its role in mTORC1 signaling, also acts as a co-chaperone of HSP90AA1/Hsp90: inhibits the ATPase activity of HSP90AA1/Hsp90, leading to activate both kinase and non-kinase client proteins of HSP90AA1/Hsp90 (PubMed:<a href="http://www.uniprot.org/citations/18403135" target="\_blank">18403135</a>). Acts as a scaffold to load client protein FLCN onto HSP90AA1/Hsp90 (PubMed:<a href="http://www.uniprot.org/citations/18403135" target="\_blank">18403135</a>). Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins (PubMed:<a href="http://www.uniprot.org/citations/18403135" target="\_blank">18403135</a>). May play a role in the signal transduction pathway of apoptosis induced by O6-methylguanine-mispaired lesions (By similarity).

### Cellular Location

Lysosome membrane. Cytoplasm. Note=Colocalizes with FLCN in the cytoplasm.

### Tissue Location


Widely expressed with highest levels in muscle, nasal mucosa, salivary gland, uvula, fat, liver, heart, placenta and pancreas (PubMed:18403135, PubMed:18663353, PubMed:27353360) Moderately expressed in the lung, small intestine, kidney and brain Lower levels detected in renal cell carcinoma than in normal kidney tissue (PubMed:18403135). Higher levels detected in oncocytoma tumors than in normal kidney. Higher levels detected in renal cell carcinoma tumors than in normal kidney tissue (PubMed:27353360)


### FNIP2 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### FNIP2 Antibody - Images





Western blot analysis of FNIP2 in mouse skeletal muscle lysate with FNIP2 antibody at (A) 1 and (B) 2  $\mu$ g/mL.

### FNIP2 Antibody - Background

FNIP2 Antibody: FNIP2 is the second protein found to interact with folliculin, the product of the Birt-Hogg-Dube (BHD) gene. Folliculin is thought to act as a tumor suppressor as mutations or loss of heterozygosity in this gene are associated with BHD syndrome-related renal tumors. Folliculin and FNIP1, a protein that shares 49% identity to FNIP2, bind to AMPK, an important energy sensor in cells that negatively regulates the mammalian target of rapamycin (mTOR), a protein that is thought to be the master switch for cell growth and proliferation. FNIP1 and FNIP2 are able to form homo- and heteromeric multimers, suggesting these proteins may have a functional relationship.

### FNIP2 Antibody - References

- Hasumi H, Baba M, Hong S-B, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. *Gene*2008; 415:60-7.
- Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dube gene product) with novel Fnip1-like (FnipL/Fnip2) protein. *Oncogene*2008; 27:5339-47.
- Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD mutations in Birt-Hogg-Dube-associated renal tumors. *J. Natl. Cancer Inst.*2005; 97:931-5.
- Baba M, Hong SB, Sharma M, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proc. Natl. Acad. Sci. USA*2006; 103:15552-7.